Skip to main content

NHS: Drugs

Question for Department of Health and Social Care

UIN 32030, tabled on 19 March 2020

To ask the Secretary of State for Health and Social Care, which medicinal products were made available on the NHS with a managed access agreement in (a) 2018-19 and (b) 2019 to date.

Answered on

27 April 2020

The National Institute for Health and Care Excellence (NICE) has recommended 11 topics for access via a Managed Access Agreement (MAA) in 2019/20 to date. In 2018/19, 12 topics were recommended via an MAA.

These topics are listed in the following table.

NICE ref

Drug

Indication

Managed access start date

2018/19

TA522

Pembrolizumab

locally advanced or metastatic urothelial cancer where cisplatin is unsuitable

27 April 2018

TA529

Crizotinib

ROS1-positive advanced non-small-cell lung cancer

31 May 2018

TA528

Niraparib

platinum-sensitive ovarian cancer after second response to chemotherapy

1 June 2018

TA540

Pembrolizumab

Relapsed or refractory classical Hodgkin lymphoma

25 July 2018

TA554

Tisagenlecleucel

relapsed or refractory B-cell acute lymphoblastic leukaemia

16 November 2018

TA553

Pembrolizumab

adjuvant treatment of resected melanoma with high risk of recurrence

19 November 2018

TA557

Pembrolizumab (with pemetrexed and platinum chemotherapy)

untreated metastatic non-squamous NSCLC

21 November 2018

TA558

Nivolumab

adjuvant treatment of resected stage III and IV melanoma

30 November 2018

TA559

Axicabtagene ciloleucel

diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies

7 December 2018

TA567

Tisagenlecleucel

relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies

1 February 2019

TA573

Daratumumab with bortezomib

Multiple myeloma

12 March 2019

TA578

Durvalumab

NSCLC

28 March 2019

2019/2020

TA579

Abemaciclib with fulvestrant

HER2-negative breast cancer after endocrine therapy

2 April 2019

TA581

Nivolumab with ipilimumab

untreated advanced renal cell carcinoma

5 April 2019

TA592

Cemiplimab

cutaneous squamous cell carcinoma

2 July 2019

TA588

Nusinersen

Spinal Muscular Atrophy

3 July 2019

TA593

Ribociclib

in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative breast cancer

17 July 2019

TA598

Olaparib

maintenance treatment of newly diagnosed BRCA-mutated advanced ovarian, fallopian tube or peritoneal cancer, after response to first-line platinum-based chemotherapy

26 July 2019

TA600

Pembrolizumab with carboplatin and paclitaxel

Metastatic squamous NSCLC

8 August 2019

TA611

Rucaparib

maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer

11 October 2019

TA619

Palbociclib in combination with fulvestrant

advanced, HR+ HER2- breast cancer after endocrine therapy

28 November 2019

TA620

Olaparib

maintenance treatment of BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube and peritoneal cancer, after response to platinum-based chemotherapy

29 November 2019

HST12

Cerliponase alfa

neuronal ceroid lipofuscinosis type 2

5 November 2019

Answered by

Department of Health and Social Care